Closed |
S0505 |
Soft Tissue Sarcomas |
3/1/2006 |
|
68% |
|
Published
|
Closed |
S0434 |
Phase II Relapsing/Resistant Myeloma Previously Treated with Bortezomib |
3/15/2006 |
|
58% |
|
Published
|
Closed |
S0521 |
Phase III Maint. vs. Obs. for Low and Intermediate Risk APL |
6/1/2007 |
|
19% |
|
Published
|
Closed |
S0535 |
Phase II ATRA, Arsenic and Mylotarg for Untreated High-Risk APL |
11/15/2007 |
|
100% |
|
|
Closed |
S0629 |
Observational and Phase II WM w/ Trans. & Maint. for Symptomatic WM |
9/15/2008 |
|
0% |
|
|
Closed |
S0711 |
Dasatinib in patients with impaired hepatic function |
10/15/2008 |
|
100% |
|
|
Closed |
S0703 |
Phase II Older Previously Untreated Non-M3 AML |
12/1/2008 |
|
93% |
|
Published
|
Closed |
S0805 |
Phase II HyperCVAD + Dasatinib with or without Allo SCT for Ph+ ALL |
9/1/2009 |
|
100% |
|
Published
|
Closed |
S1007 |
ADJUVANT: Phase III Randomized Endocrine Therapy +/- Chemo according to RS |
1/15/2011 |
|
100% |
|
|
Closed |
S0820 |
Adenoma (and Second Primary) Prevention Trial |
3/1/2013 |
|
91% |
|
|
Closed |
S1200 |
Randomized trial with acupuncture for joint symptoms related to AIs in women with early stg brst ca |
3/27/2012 |
|
99% |
|
|
Closed |
S1211 |
PII Optimal Induction for HRMM |
10/12/2012 |
|
100% |
|
|
Closed |
S1221 |
BRAF Mutant Metastatic Cancer |
7/1/2013 |
|
39% |
|
|
Closed |
S1313 |
Ph Ib/II Rando mFOLFIRINOX+PEGPH20 vs mFOLFIRINOX Alone in Good PS Met Pancreatic Adenocarcinoma |
1/6/2014 |
|
73% |
|
|
Closed |
S1400 |
Lung Master Protocol Advanced Squamous Cell NSCLC |
6/15/2014 |
|
|
|
|
Closed |
S1400C |
Lung-MAP S1400C: CDK4/6 - Palbociclib |
6/15/2014 |
|
91% |
|
|
Closed |
S1316 |
Surgery vs Non-Surgical Management for MBO |
3/9/2015 |
|
100% |
|
|
Closed |
S1505 |
Perioperative FOLFIRINOX vs Gem/nab-Pac for Resectable Panc Adeno |
10/12/2015 |
|
98% |
|
|
Closed |
S1404 |
MK-3475, Interferon, Resected High-Risk Melanoma |
10/15/2015 |
|
98% |
|
|
Closed |
S1415CD |
Trial Assessing CSF Prescribing, Effectiveness and Risk (TRACER) |
10/7/2016 |
|
93% |
|
|